Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03745781 · ClinicalTrials.gov registry record · Early Phase 1
Open-Label Placebo for Functional Dyspepsia
A Early Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
NCT03745781: Clinical Trial Early Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
NCT03745781 is a Early Phase 1 study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 21 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03745781, a Early Phase 1 study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The study is evaluating the efficacy of open-label placebo for the treatment of functional dyspepsia.
Primary Outcome
How severe have your dyspepsia symptoms been over the past 7 days (on a VAS from 0-100)?
Interventions
- DRUG Placebos
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-12-01 |
| Est. Completion | 2019-10-07 |
| Phase | Early Phase 1 |
Why NCT03745781 stopped before completion
NCT03745781 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 1 intervention - of which Placebos is the first listed.
NCT03745781 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03745781 about?
NCT03745781 is a clinical study titled "Open-Label Placebo for Functional Dyspepsia". The study is evaluating the efficacy of open-label placebo for the treatment of functional dyspepsia.
What is the current status of trial NCT03745781?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2018-12-01. Estimated completion is 2019-10-07.
What interventions are being tested in trial NCT03745781?
The interventions under investigation include: Placebos (DRUG).
Who is sponsoring clinical trial NCT03745781?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03745781's enrollment target sits among peer trials
21 1130th of 2000 higher than 844 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI